Introduction: Dendritic cell therapy is a promising therapeutic therapy for cancer. Various methods have been developed to culture and expand dendritic cells in vitro. However, most methods have used fetal bovine serum (FBS)-supplemented media to induce and expand monocytes; cells prepared by these methods cannot be used in the clinic. Therefore, this study aims to develop new methods to produce dendritic cells (DCs) from monocytes using serum-free medium. Methods: mononuclear cells (MNCs) were isolated from human umbilical cord blood by gradient centrifugation. They were then induced into DCs using 3 kinds of inducing media: M1 (medium supplemented with FBS), M2 (medium supplemented with human serum (HS) from umbilical cord blood), and M3 (medium supplemented with platelet-rich plasma (PRP) from umbilical cord blood) at 10% supplement. The MNCs were induced to immature DCs (iDCs) by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, and matured by tumor necrosis factor (TNF)-alpha. The phenotype of the DCs were evaluated by flow cytometry, immunohistochemistry, and in vitro phagocytic assay. Results: The results showed that all cells in the groups exhibited the shape of dendritic cells.Immunohistochemistry analysis showed that the mature cultured cells in the 3 kinds of media (i.e. supplemented with either FBS, HS, or PRP) were all CD86+HLA-DR+CD14-, representative of mature DC (mDC) phenotype. DCs cultured in HS and PRP media also exhibited FITC-Dextran phagocytosis and showed IL-12 gene expression similar to those DCs cultured in FBS medium. Conclusion: The results of the present study suggest that HS or PRP can replace FBS to produce DCs in vitro for clinical use.